Literature DB >> 21362348

Overview of antiretroviral treatment in China: advancement and challenges.

Ling Luo1, Tai-Sheng Li.   

Abstract

As the severity of the HIV epidemic in China grew, National Free Antiretroviral Treatment (ART) Program was announced since 2003. Even though there still were many difficulties, China had obtained great achievements in fighting against HIV. Over 52 000 adult patients had received first-line HAART thus far and the mortality of AIDS in China decreased significantly. This paper presents an overview of the HIV/AIDS epidemic in China; the status of national free ART program, the difficulties suffered and the achievements made since the initiation of program and the challenges ahead for continued progress for China. This paper also provides suggestions to overcome these challenges.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21362348

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  10 in total

1.  Editorial commentary: China, HIV, and syphilis among men who have sex with men: an urgent call to action.

Authors:  Kathryn E Muessig; Myron S Cohen
Journal:  Clin Infect Dis       Date:  2013-04-11       Impact factor: 9.079

2.  Feasibility, reliability and validity of the Chinese simplified version of the MOS-HIV health survey among AIDS patients in China.

Authors:  Zhang-Jun Huang; Min Tian; Se-Ying Dai; Dong-Qing Ye
Journal:  Qual Life Res       Date:  2012-03-04       Impact factor: 4.147

3.  Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China.

Authors:  Pengtao Liu; Yinghui You; Lingjie Liao; Yi Feng; Yiming Shao; Hui Xing; Guanghua Lan; Jianjun Li; Yuhua Ruan; Dan Li
Journal:  BMC Infect Dis       Date:  2022-05-04       Impact factor: 3.667

4.  In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors.

Authors:  Hao Wu; Xiao-Min Zhang; Hao-Jie Zhang; Qiwei Zhang; Zhiwei Chen; Jian-Dong Huang; Shui-Shan Lee; Bo-Jian Zheng
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01-08       Impact factor: 2.205

Review 5.  Treatment of acquired immunodeficiency syndrome with Chinese medicine in China: opportunity, advancement and challenges.

Authors:  Zhi-Bin Liu; Xin Wang; Hui-Juan Liu; Yan-Tao Jin; Hui-Jun Guo; Zi-Qiang Jiang; Zhen Li; Li-Ran Xu
Journal:  Chin J Integr Med       Date:  2013-07-29       Impact factor: 1.978

6.  Task shifting of HIV/AIDS case management to Community Health Service Centers in urban China: a qualitative policy analysis.

Authors:  Fuchang Ma; Fan Lv; Peng Xu; Dapeng Zhang; Sining Meng; Lahong Ju; Huihui Jiang; Liping Ma; Jiangping Sun; Zunyou Wu
Journal:  BMC Health Serv Res       Date:  2015-07-02       Impact factor: 2.655

7.  Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province, China.

Authors:  Hanping Li; Min Zhong; Wei Guo; Daomin Zhuang; Lin Li; Yongjian Liu; Zuoyi Bao; Siyang Liu; Xiaolin Wang; Tianyi Li; Shaomin Yang; Jingyun Li
Journal:  PLoS One       Date:  2013-08-29       Impact factor: 3.240

8.  Drug resistance evolution in patients with human immunodeficiency virus-1 under long-term antiretroviral treatment-failure in Yunnan Province, China.

Authors:  Jianjian Li; Yawen Xu; Jiafa Liu; Bihui Yang; Cuixian Yang; Mi Zhang; Xingqi Dong
Journal:  Virol J       Date:  2019-01-08       Impact factor: 4.099

9.  Survey of Pretreatment HIV Drug Resistance and Genetic Transmission Network Analysis Among HIV Patients in a High Drug-Use Area of Southwest China.

Authors:  Lei Liu; Aobo Dong; Lingjie Liao; Yi Feng; Yiming Shao; Shu Liang; Yuhua Ruan; Hui Xing
Journal:  Curr HIV Res       Date:  2019       Impact factor: 1.581

10.  A Real-world Evidence-based Management of HIV by Differential Duration HAART Treatment and its Association with Incidence of Oral Lesions.

Authors:  Wen Shu; Fei Du; Jin-Song Bai; Ling-Yun Yin; Kai-Wen Duan; Cheng-Wen Li
Journal:  Curr HIV Res       Date:  2022       Impact factor: 1.341

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.